Phase 2Active, not recruiting
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
- Sponsor
- Andrew Yee, MD (Academic or other)
- Enrollment
- 44 enrolled
- Conditions
- Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse; Relapse
- Interventions
- Daratumumab; Carfilzomib; Pomalidomide; Dexamethasone
- Ages
- adults, older adults
- Registry
- NCT04176718
Full record on ClinicalTrials.gov
From the registry
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide
Primary outcomes
- Objective response rate of the daratumumab, carfilzomib, pomalidomide, and dexamethasone combination
- Number of dose limiting toxicity grade 4 or higher treatment related
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered